What question did this study set out to answer?

This research examines the effects of loading dose β-lactam therapy on treatment outcomes for KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients.

March 7, 2026Open Access

Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study

Key Points

This research examines the effects of loading dose β-lactam therapy on treatment outcomes for KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients.
Conducted a real world study in non-ICU patients with KPC-Kp BSIs.
Analyzed outcomes associated with β-lactam loading dose regimen.
Evaluated microbiological clearance, ICU transfers, and hospital stay length.
Faster microbiological clearance observed with loading dose regimen.
Reduced need for ICU transfer noted among non-ICU patients.
Shorter hospital stays reported without increased toxicity.
Mortality showed a non-significant trend towards improvement.

Abstract

In non-ICU KPC-Kp BSIs, a β-lactam loading dose regimen was associated with faster microbiological clearance, reduced ICU transfer and shorter hospital stay, without added toxicity. Mortality showed a non-significant trend towards improvement. Pragmatic LD strategies may enhance early β-lactam exposure where therapeutic drug monitoring (TDM) is unavailable. Prospective PK/PD-guided studies are warranted.

Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study

Key Points

Abstract

Cite This Study